Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen T Durant

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|February 2, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390Kurt G Pike, Thomas A Hunt, Bernard Barlaam, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Medicinal Chemistry|February 2, 2024
Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood-Brain Barrier: The Discovery of AZD1390Kurt G Pike, Thomas A Hunt, Bernard Barlaam, et al.
Nature Communications|May 24, 2024
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumoursDiego Dibitetto, Martin Liptay, Francesca Vivalda, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Science Advances|June 26, 2018
The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor modelsStephen T Durant, Li Zheng, Yingchun Wang, et al.
Molecular Cancer Therapeutics|May 18, 2018
Orally Bioavailable and Blood-Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in MiceJeremy Karlin, Jasmine Allen, Syed F Ahmad, et al.
Pageof 3